TrialWatch
Natural History Study of the Development of Type 1 Diabetes
ClinicalTrials.gov Identifier: NCT00097292
Over the last decade, our understanding of the underlying mechanisms leading to type 1 diabetes has improved considerably. However, we still do not completely understand what differentiates individuals at-risk for developing type 1 who proceed to develop diabetes from those who live a diabetes-free life. TrialNet, an international network dedicated to the study, prevention, and early treatment of type 1 diabetes, initiated a Natural History Study to enhance our understanding of people at-risk for developing the disease. The study screens relatives of people with type 1 diabetes to identify those at-risk for developing it by testing for certain biological markers. You may be eligible if you are 1 to 45 years old with an immediate family member (child, parent, or sibling) with type 1 diabetes or if you are 1 to 20 years old with an extended family member (cousin, niece, nephew, aunt, uncle, grandparent, or half-sibling) with type 1 diabetes. Participants may also be offered the opportunity to enter into a prevention study (such as the Oral Insulin prevention study) or an early treatment study if they are diagnosed with type 1 diabetes while participating in the Natural History Study. The study is recruiting at 19 locations worldwide (and chaired by diaTribe advisory board member Dr. Jay Skyler of the University of Miami!). To find a center near you and learn more about this trial, contact the TrialNet central information center by calling 1-800-425-8361.
Effects of LY2189265 on Glycemic Control in Patients with Type 2 Diabetes
ClinicalTrials.gov Identifier: NCT00791479
LY2189265 is a GLP-1 therapy for the treatment of type 2 diabetes currently in phase 2 clinical trials. This 12-week study will determine the safety and effectiveness of LY2189265. GLP-1 analogs are a relatively recent class of drugs for type 2 diabetes that have the potential to significantly decrease A1c and reduce body weight without causing hypoglycemia. Currently, exenatide (also known as Byetta) is the only available GLP-1 therapy in the US. However, unlike exenatide, LY2189265 is taken in the form of once-weekly subcutaneous injections. To be considered for enrollment, eligible patients must be 18 to 75 years old and controlling their diabetes through either only diet and exercise or metformin and are willing to discontinue this medication. Patients can have an A1c ranging from 6.5% to 9.5% and females cannot become pregnant during the study. The study is being conducted at 12 centers across California, Indiana, Kansas, Michigan, North Carolina, Pennsylvania, South Carolina, and Wisconsin; to learn more about the trial and how to get involved, call 1-877-285-4559.
Episodic Intensive Blood Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes
ClinicalTrials.gov Identifier: NCT00674986
This study aims to determine whether the use of intensive glucose monitoring with the Accu-Chek Aviva in non-insulin treated type 2 diabetes patients has a positive effect on overall blood sugar. The Accu-Chek Aviva will be used in combination with the Accu-Chek 360 view blood glucose analysis system. The study will evaluate the effect on patients’ glucose control by measuring A1c after after 12 months. We are very interested in this study, since intensive glucose testing is strongly suggested for insulin-treated diabetes patients but typically not for non-insulin treated patients. However, as a result of checking blood glucose multiple times a day, non-insulin treated patients may become more aware of their glucose levels and encourage these patients to take better control of their diabetes. To be considered for enrollment, patients must be 35 years of age or older and have an A1c between 7.5% and 11%. In addition, eligible patients must be controlling their diabetes using diet and exercise, a prescription oral medication, or an injectable incretin therapy. The study is being conducted at 17 centers across Alabama, Florida, Georgia, Illinois, Indiana, North Carolina, Ohio, Pennsylvania, South Carolina, Tennessee, and Virginia; to learn more about the trial and how to get involved, call 1- 800-526-6367 and use the Reference Study ID Number RD000590.